Details
Stereochemistry | ACHIRAL |
Molecular Formula | 4CO3.6Mg.2HO.5H2O |
Molecular Weight | 509.9567 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O
InChI
InChIKey=UOVKYUCEFPSRIJ-UHFFFAOYSA-D
InChI=1S/4CH2O3.6Mg.7H2O/c4*2-1(3)4;;;;;;;;;;;;;/h4*(H2,2,3,4);;;;;;;7*1H2/q;;;;6*+2;;;;;;;/p-10
DescriptionSources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Sources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Struvite, a crystalline substance first identified in the 18th century, is composed of magnesium ammonium
phosphate. Struvite urinary stones are also known as ‘infection stones’, and account for 15%-20% of all urinary stones. Bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation.
CNS Activity
Sources: DOI: 10.1002/0471238961.0218151310010311.a02Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQChttps://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506
Curator's Comment: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date2016 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of manganese, calcium, magnesium and lithium on the ouabain-induced seizure. | 1977 |
|
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors. | 1977 Apr |
|
[Magnesium--an alternative in treatment resistant tachyarrhythmias]. | 1977 May 30 |
|
Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms. | 1979 Nov |
|
Characterization of the prolactin receptor in human prostate. | 1983 Nov |
|
Symptomatic hypercalcaemia precipitated by magnesium therapy. | 1985 Jan |
|
Regulation of membrane histamine H1-receptor binding sites by guanine nucleotides, mono- and divalent cations. | 1986 Apr |
|
Metal: ATP characteristics of insulin- and epidermal growth factor-stimulated phosphorylation in detergent extracts of rat liver plasma membranes. | 1986 Sep |
|
Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats. | 1987 Mar 30 |
|
Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. | 1988 Sep 1 |
|
Effect of magnesium diet in gentamicin-induced acute renal failure in rats. | 1989 |
|
Polylysine specifically activates the insulin-dependent insulin receptor protein kinase. | 1989 Jun 15 |
|
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium]. | 1989 Sep |
|
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain. | 1990 Feb 5 |
|
Role of magnesium in cardiac tachyarrhythmias. | 1990 Jun 19 |
|
Magnesium inhibits the hypertensive but not the cardiotonic actions of low-dose epinephrine. | 1991 Jun |
|
Persistent paralysis in critically ill patients after long-term administration of vecuronium. | 1992 Aug 20 |
|
[Heart rate disorders in potassium and magnesium deficiency]. | 1992 Sep 7 |
|
['Cardiac ballet' with and without amiodarone]. | 1993 Jan 13 |
|
Overexpressed protein kinase C-delta and -epsilon subtypes in NIH 3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake. | 1994 Feb 18 |
|
Cocaine-induced cerebrovasospasm and its possible mechanism of action. | 1994 Mar |
|
Differential modulation of alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors expressed in Xenopus oocytes by flufenamic acid and niflumic acid. | 1995 Mar |
|
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. | 1996 Jun |
|
Aluminum is a weak agonist for the calcium-sensing receptor. | 1999 May |
|
Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density. | 2000 Aug |
|
Familial hypomagnesemia--hypercalciuria and pseudotumor cerebri. | 2001 |
|
Evidence supporting a role for KCl cotransporter in the thick ascending limb of Henle's loop. | 2001 Nov |
|
Magnesium bromide mediated highly diastereoselective heterogeneous hydrogenation of olefins. | 2002 Apr 18 |
|
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003 May 2 |
|
Enhancement of endotoxin-induced vascular hyporeactivity to phenylephrine in the thoracic aortas of Mg-deficient rats ex vivo. | 2003 Oct 10 |
|
Conformational changes in sarcoplasmic reticulum Ca(2+)-ATPase mutants: effect of mutations either at Ca(2+)-binding site II or at tryptophan 552 in the cytosolic domain. | 2006 Apr 25 |
|
Further characterization of mammalian ceramide kinase: substrate delivery and (stereo)specificity, tissue distribution, and subcellular localization studies. | 2006 Feb |
|
Activation and enzymatic characterization of recombinant human kallikrein 8. | 2006 Jun |
|
Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. | 2006 Mar |
|
Kinetic properties of chimeric class I aldehyde dehydrogenases for retinal isomers. | 2006 Oct |
|
Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and beta-adrenergic desensitization. | 2007 Mar |
|
Treatment of migraine with prophylactic drugs. | 2008 Oct |
|
Cocaine use disorders and serum magnesium profile. | 2009 |
|
Differential binding of inorganic particles to MARCO. | 2009 Jan |
|
Involvement of transient receptor potential melastatin-related 7 (TRPM7) channels in cadmium uptake and cytotoxicity in MC3T3-E1 osteoblasts. | 2010 Dec 15 |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. | 2011 Feb |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition. | 2011 Feb |
|
Millimolar Mn2+ influences agonist binding to 5-HT1A receptors by inhibiting guanosine nucleotide binding to receptor-coupled G-proteins. | 2011 Jan |
|
NADH fluorescence lifetime analysis of the effect of magnesium ions on ALDH2. | 2011 May 30 |
|
Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1. | 2013 Feb 25 |
|
Catalytic contribution of threonine 244 in human ALDH2. | 2013 Feb 25 |
|
A Soft Grip: Magnesium Complexes with a Phosphine-Modified Phosphonium Diylidic Lewis Base. | 2016 Nov 21 |
|
Nano-layered magnesium fluoride reservoirs on biomaterial surfaces strengthen polymorphonuclear leukocyte resistance to bacterial pathogens. | 2017 Jan 5 |
|
Magnesium amide catalyzed selective hydroboration of esters. | 2017 Mar 27 |
|
Antenatal Exposure to Magnesium Sulfate and Spontaneous Intestinal Perforation and Necrotizing Enterocolitis in Extremely Preterm Neonates. | 2017 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27995243
Curator's Comment: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form
https://www.ncbi.nlm.nih.gov/pubmed/20647692
Murine osteomyelitis model: medical pure titanium plates in size of 10 mm × 10 mm × 1 mm
were used for the deposition of Magnesium Fluoride (MgF2) film.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-504(II)
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
||
|
JECFA EVALUATION |
INS-504(II)
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1363704
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB14419MIG
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
PRIMARY | |||
|
m6994
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
YQO029V1L4
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
PRIMARY | |||
|
39409-82-0
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
PRIMARY | |||
|
100000076800
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
PRIMARY | |||
|
73415762
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
PRIMARY | |||
|
YQO029V1L4
Created by
admin on Fri Dec 15 15:54:29 GMT 2023 , Edited by admin on Fri Dec 15 15:54:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
ACTIVE MOIETY
SUBSTANCE RECORD